Compare BX & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BX | SNY |
|---|---|---|
| Founded | 1985 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.4B | 107.3B |
| IPO Year | 2007 | N/A |
| Metric | BX | SNY |
|---|---|---|
| Price | $128.29 | $47.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 5 |
| Target Price | ★ $161.25 | $58.00 |
| AVG Volume (30 Days) | ★ 6.2M | 2.9M |
| Earning Date | 04-23-2026 | 04-23-2026 |
| Dividend Yield | ★ 3.64% | 3.33% |
| EPS Growth | ★ 6.91 | N/A |
| EPS | ★ 3.87 | N/A |
| Revenue | ★ $14,450,265,000.00 | N/A |
| Revenue This Year | $14.23 | $3.86 |
| Revenue Next Year | $21.79 | $5.64 |
| P/E Ratio | $33.72 | ★ $6.14 |
| Revenue Growth | ★ 9.22 | N/A |
| 52 Week Low | $101.73 | $43.32 |
| 52 Week High | $190.09 | $55.73 |
| Indicator | BX | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 65.74 | 56.99 |
| Support Level | $125.27 | $46.88 |
| Resistance Level | $136.49 | $48.49 |
| Average True Range (ATR) | 4.33 | 0.71 |
| MACD | 2.49 | 0.10 |
| Stochastic Oscillator | 83.94 | 65.94 |
Blackstone is the world's largest alternative-asset manager with $1.242 trillion in total asset under management, including $906.2 billion in fee-earning assets under management, at the end of September 2025. The company operates with scale in each of its major product lines: private equity (26% of fee-earning AUM and 33% of base management fees), real estate/real assets (31% and 35%), private credit (34% and 25%), and other alternatives (9% and 7%). While the firm primarily serves institutional investors (84% of AUM), it also caters to clients in the high-net-worth channel (16%). Blackstone operates through 25 offices in the Americas (8), Europe and the Middle East (9), and the Asia-Pacific region (8).
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.